ADC Therapeutics Announces LOTIS-7 Trial Update on ZYNLONTA Combination in Relapsed DLBCL
ADC Therapeutics SA will update on the LOTIS-7 Phase 1b trial of ZYNLONTA® with glofitamab in relapsed DLBCL patients. A webcast on December 3, 2025, will present the study's safety and efficacy data. The original content was published via PR Newswire.
ADC Therapeutics SA has announced that it will provide an update on the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The company will host a corporate webcast to share updated data on December 3, 2025. Results from the study have not yet been presented and will be discussed during the upcoming webcast. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: NY37466) on December 02, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
